China Sky One Medical's Tianlong subsidiary to focus R&D efforts on antibiotics and cardiac drugs

Leading Chinese over-the-counter medicines company China Sky One Medical says that its wholly-owned subsidiary Heilongjiang Tianlong Pharmaceutical will change its R&D focus from external use medicines to antibiotics and cardiac drugs.

The change is designed to build a solid foundation for the company's future growth. Tianlong has one of the most complete portfolios of external use medicines in China, according to its parent. By focusing on the development of antibiotics and cardiac drugs, China Sky One Medical expects that Tianlong will be able to benefit from the increasing demand for prescription drugs as basic medical insurance coverage expands in China. Antibiotics represent the largest drug category in China, accounting for 20%-25% of total sales of western medicines. Medicines for the treatment of cardiac diseases represent the third largest drug category following cancer drugs, and account for roughly 15% of total sales of chemical medicines in China.

Five new antibiotic and two cardiac launches planned